以色列 - 希伯来文 - Ministry of Health

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 1005.04 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin

以色列 - 希伯来文 - Ministry of Health

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin

以色列 - 希伯来文 - Ministry of Health

neopharm ltd - thalidomide - קפסולה קשיחה - thalidomide 50 mg - thalidomide

以色列 - 希伯来文 - Ministry of Health

teva israel ltd - cetrimide; chlorhexidine hydrochloride - קרם - cetrimide 0.5 %w/w; chlorhexidine hydrochloride 0.1 %w/w - chlorhexidine, combinations - chlorhexidine, combinations - first aid antiseptic for external use in treatment for minor injuries, wounds and burns.

以色列 - 希伯来文 - Ministry of Health

j-c health care ltd - doxorubicin hydrochloride - liposome for infusion - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin - doxorubicin - first or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease the treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatmnt. as monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. in combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

以色列 - 希伯来文 - Ministry of Health

pfizer pharmaceuticals israel ltd - temsirolimus - תרכיז להכנת תמיסה לאינפוזיה - temsirolimus 25 mg/ml - temsirolimus - temsirolimus - first line treatment of patients with advanced renal cell carcinoma.torisel is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma.

以色列 - 希伯来文 - Ministry of Health

teva israel ltd - bimatoprost; timolol as maleate - טיפות עיניים - timolol as maleate 5 mg / 1 ml; bimatoprost 0.3 mg / 1 ml - timolol, combinations

以色列 - 希伯来文 - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

以色列 - 希伯来文 - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

以色列 - 希伯来文 - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.